We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Radiosensitization of orthotopic GIC-driven glioblastoma by doxycycline causes skin damage.
- Authors
Frosina, Guido; Marcello, Diana; Daga, Antonio; Marubbi, Daniela
- Abstract
Doxycycline (DXC) is a tetracycline antibiotic which has been proposed as a breast cancer radiosensitizer by specifically reducing the expression of the DNA repair enzyme DNA PK in breast cancer initiating cells. Since DXC presents favorable pharmacokinetics properties including the capacity to cross the blood-brain barrier, it has been hypothesized that it could radiosensitize brain tumors as well. We have investigated the radiosensitizing capacity of DXC towards human glioma initiating cells (GIC)-driven orthotopic glioblastomas (GB) in NOD/SCID mice that faithfully mimic the growth properties of the clinical tumors of origin. DXC at 10 mg/Kg body weight was subcutaneously delivered daily, 5 days/week for 4 weeks. At the same time, radiotherapeutic fractions of 0.25 Gy to the head were delivered every 3-4 days (twice/week) for 15 weeks. No survival advantage was observed in DXC-treated mice as compared to vehicle-treated mice by this radiosensitizing protocol. On the contrary, skin damage with hair loss and deep ulcers were observed after 4 weeks in DXC-treated mice leading to discontinuation of drug treatment. These results do not support the use of DXC as a radiosensitizer for brain tumors and indicate skin damage as an important side effect of DXC.
- Subjects
TETRACYCLINES; DRUG side effects; DNA ligases; BRAIN tumors; DNA repair; BLOOD-brain barrier
- Publication
Radiation Oncology, 2019, Vol 14, Issue 1, pN.PAG
- ISSN
1748-717X
- Publication type
journal article
- DOI
10.1186/s13014-019-1266-4